Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-51.72%
0%
-51.72%
6 Months
-73.38%
0%
-73.38%
1 Year
-74.07%
0%
-74.07%
2 Years
-84.44%
0%
-84.44%
3 Years
-88.24%
0%
-88.24%
4 Years
-87.63%
0%
-87.63%
5 Years
-93.4%
0%
-93.4%
IntegraGen SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-5.38%
EBIT Growth (5y)
-203.01%
EBIT to Interest (avg)
-0.37
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
4.43
Tax Ratio
9.65%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.58
EV to EBIT
0.25
EV to EBITDA
0.25
EV to Capital Employed
-0.25
EV to Sales
-0.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-14.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
12.50
13.20
-5.30%
Operating Profit (PBDIT) excl Other Income
-0.20
0.10
-300.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.20
-0.00
Operating Profit Margin (Excl OI)
-32.50%
-8.30%
-2.42%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -5.30% vs 16.81% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022
About IntegraGen SA 
IntegraGen SA
Pharmaceuticals & Biotechnology
Integragen SA is a France-based company active in the healthcare sector. It researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. It uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). It also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The Company also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.
Company Coordinates 
Company Details
Genopole Campus 1, Genavenir 8 5 rue Henri Desbrueres EVRY None : 91000
Registrar Details






